SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced new data from a collaboration with Duke University…

Evaxion · PRESS-RELEASE filed Apr 17, 2026 at 15:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 17, 2026 at 15:00 ET

Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens for use in personalized vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The findings, to be presented at AACR 2026, demonstrate a novel antigen source that could improve vaccine efficacy in low mutational burden cancers.

  • AI-Immunology™ platform identified ERV-derived antigens in glioblastoma tumor samples, a novel target source absent in normal tissue.
  • Data shows feasibility of including both ERV antigens and neoantigens in personalized vaccines for most glioblastoma patients.
  • Immunologic responses to ERV antigens were experimentally confirmed, supporting clinical potential.
  • Results to be presented at AACR Annual Meeting on April 22, 2026, increasing scientific visibility.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access